Biological activities of HDL subpopulations and their relevance to cardiovascular disease

Trends in Molecular Medicine

Volumn 17, Issue 10, 2011, Pages 594-603

  Camont, Laurent ^a,b   Chapman, M John ^a,b,c   Kontush, Anatol ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID TRANSFER PROTEIN; REACTIVE OXYGEN METABOLITE; TORCETRAPIB; TRIACYLGLYCEROL; VASODILATOR AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BACTERIAL CLEARANCE; BIOGENESIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL MIGRATION; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DRUG BINDING; DYSLIPIDEMIA; HUMAN; INFECTION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LEUKOCYTE ACTIVATION; LIPID PEROXIDATION; MORBIDITY; MORTALITY; NEUTROPHIL CHEMOTAXIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PROTEIN METABOLISM; REVIEW; SIDE EFFECT; THROMBOCYTE ACTIVATION; VASODILATATION;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; HUMANS; LIPOPROTEINS, HDL; RISK FACTORS;

EID: 80053574090     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.05.013     Document Type: Review

References (68)

1. Di Angelantonio E., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
2. Barter P.J., et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 2007, 357:2109-2122.
3. Khera A.V., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 2011, 364:127-135.
4. Rosenson R.S., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 2011, 57:392-410.
5. Davidson W.S., Thompson T.B. The structure of apolipoprotein A-I in high density lipoproteins. J. Biol. Chem. 2007, 282:22249-22253.
6. Vaisar T., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 2007, 117:746-756.
7. Davidson W.S., et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 2009, 29:870-876.
8. Kontush A., et al. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1881-1888.
9. Gordon S.M., et al. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J. Proteome Res. 2010, 9:5239-5249.
10. Kontush A., et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1843-1849.
11. de Souza J.A., et al. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J. Cell. Mol. Med. 2010, 14:608-620.
12. de Souza J.A., et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 2008, 197:84-94.
13. Kontush A., Chapman M.J. Functionally defective HDL: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol. Rev. 2006, 3:342-374.
14. Movva R., Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin. Chem. 2008, 54:788-800.
15. Kontush A., Chapman M.J. Antiatherogenic small, dense HDL - guardian angel of the arterial wall?. Nat. Clin. Pract. Cardiovasc. Med. 2006, 3:144-153.
16. Tall A.R. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J. Intern. Med. 2008, 263:256-273.
17. Adorni M.P., et al. The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res. 2007, 48:2453-2462.
18. Favari E., et al. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 2009, 48:11067-11074.
19. Asztalos B.F., et al. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J. Lipid Res. 2005, 46:2246-2253.
20. de la Llera-Moya M., et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 2010, 30:796-801.
21. Gonzalez M.C., et al. The central type Y amphipathic alpha-helices of apolipoprotein AI are involved in the mobilization of intracellular cholesterol depots. Arch. Biochem. Biophys. 2008, 473:34-41.
22. Miyazaki M., et al. Smaller discoidal high-density lipoprotein particles form saddle surfaces, but not planar bilayers. Biochemistry 2009, 48:7756-7763.
23. Rothblat G.H., Phillips M.C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 2010, 21:229-238.
24. Yancey P.G., et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem. 2000, 275:36596-36604.
25. Sankaranarayanan S., et al. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J. Lipid Res. 2009, 50:275-284.
26. Shuhei N., et al. Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Dis. 2010, 9:104.
27. Kontush A., Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol. 2010, 21:312-318.
28. Zerrad-Saadi A., et al. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:2169-2175.
29. Nicholls S.J., et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005, 111:1543-1550.
30. Yvan-Charvet L., et al. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol. 2010, 30:139-143.
31. Nofer J.-R., Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med. 2005, 15:265-271.
32. Rye K.-A., et al. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 2009, 50:S195-S200.
33. Nicholls S.J., et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J. Am. Coll. Cardiol. 2006, 48:715-720.
34. Baker P.W., et al. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J. Lipid Res. 1999, 40:345-353.
35. Park C.T., Wright S.D. Fibrinogen is a component of a novel lipoprotein particle: factor H-related protein (FHRP)-associated lipoprotein particle (FALP). Blood 2000, 95:198-204.
36. Kimura T., et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1283-1288.
37. Calabresi L., et al. High-density lipoprotein quantity or quality for cardiovascular prevention?. Curr. Pharm. Des. 2010, 16:1494-1503.
38. Calabresi L., et al. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1724-1731.
39. Drew B.G., et al. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:6999-7004.
40. Nofer J.R., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 2004, 113:569-581.
41. Sattler K., Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc. Res. 2009, 82:201-211.
42. Terasaka N., et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J. Clin. Invest. 2008, 118:3701-3713.
43. Oravec S., et al. The effect of high density lipoprotein subfractions on endothelial eicosanoid secretion. Thromb. Res. 1998, 92:65-71.
44. Warnholtz A., et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis 2009, 204:216-221.
45. Hermann F., et al. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thromb. Res. 2009, 123:460-465.
46. Nofer J.R., et al. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin. Exp. Pharmacol. Physiol. 2010, 37:726-735.
47. Johnson J.D., et al. UC/MALDI-MS analysis of HDL; evidence for density-dependent post-translational modifications. Int. J. Mass Spectrom. 2007, 268:227-233.
48. Li Y., et al. Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. Eur. J. Pharmacol. 2008, 590:417-422.
49. Shiflett A.M., et al. Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J. Biol. Chem. 2005, 280:32578-32585.
50. Park C.T., Wright S.D. Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins. J. Biol. Chem. 1996, 271:18054-18060.
51. Rye K.A., Barter P.J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 2004, 24:421-428.
52. von Eckardstein A., et al. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 2001, 21:13-27.
53. Chapman M.J., et al. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J. 2010, 31:149-164.
54. Santamarina-Fojo S., et al. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1750-1754.
55. Curtiss L.K., et al. What is so special about apolipoprotein AI in reverse cholesterol transport?. Arterioscler. Thromb. Vasc. Biol. 2006, 26:12-19.
56. Williams P.T., Feldman D.E. Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. Atherosclerosis 2010, 214:196-202.
57. Schaefer E.J., Asztalos B.F. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Am. J. Cardiol. 2007, 100:S25-S31.
58. Asztalos B.F., et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2181-2187.
59. Asztalos B.F., Schaefer E.J. High-density lipoprotein subpopulations in pathologic conditions. Am. J. Cardiol. 2003, 91:12E-17E.
60. van der Steeg W.A., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol. 2008, 51:634-642.
61. Parra H.J., et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler. Thromb. 1992, 12:701-707.
62. Asztalos B., et al. Role of free apolipoprotein A-I in cholesterol efflux. Formation of pre-alpha-migrating high-density lipoprotein particles. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1630-1636.
63. Duriez P., Fruchart J.C. High-density lipoprotein subclasses and apolipoprotein A-I. Clin. Chim. Acta 1999, 286:97-114.
64. Rosenson R.S., et al. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) Trial. Am. J. Cardiol. 2002, 90:89-94.
65. Otvos J.D., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563.
66. El Harchaoui K., et al. High-density lipoprotein particle size and concentration and coronary risk. Ann. Intern. Med. 2009, 150:84-93.
67. Mora S., et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931-939.
68. Schaefer E.J., et al. Marked HDL deficiency and premature coronary heart disease. Curr. Opin. Lipidol. 2010, 21:289-297.